MX2020011804A - Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas. - Google Patents

Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas.

Info

Publication number
MX2020011804A
MX2020011804A MX2020011804A MX2020011804A MX2020011804A MX 2020011804 A MX2020011804 A MX 2020011804A MX 2020011804 A MX2020011804 A MX 2020011804A MX 2020011804 A MX2020011804 A MX 2020011804A MX 2020011804 A MX2020011804 A MX 2020011804A
Authority
MX
Mexico
Prior art keywords
hbv
virus
hepatitis
vectors
vaccines
Prior art date
Application number
MX2020011804A
Other languages
English (en)
Inventor
Soumitra Roy
Helen Horton
Pooter Dorien De
Daniel Boden
Jean- Marc Edmond Fernand Marie NEEFS
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MX2020011804A publication Critical patent/MX2020011804A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen polinucleótidos que codifican para el antígeno de core y el antígeno de polimerasa del virus de la hepatitis B (HBV), y combinaciones relacionadas; se describen también vectores, tales como plásmidos de ADN o vectores virales, que expresan los antígenos de core y polimerasa de HBV, y composiciones inmunógenas que contienen los vectores de expresión; se describen también métodos para inducir una respuesta inmune contra el HBV o para tratar una enfermedad inducida por el HBV, en particular en individuos que tienen infección crónica por HBV, usando las composiciones inmunógenas.
MX2020011804A 2017-12-19 2020-07-13 Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas. MX2020011804A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762607426P 2017-12-19 2017-12-19
IB2017058142 2017-12-19

Publications (1)

Publication Number Publication Date
MX2020011804A true MX2020011804A (es) 2020-12-07

Family

ID=65199441

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020006480A MX2020006480A (es) 2017-12-19 2018-12-18 Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas.
MX2020011802A MX2020011802A (es) 2017-12-19 2020-07-13 Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas.
MX2020011804A MX2020011804A (es) 2017-12-19 2020-07-13 Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2020006480A MX2020006480A (es) 2017-12-19 2018-12-18 Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas.
MX2020011802A MX2020011802A (es) 2017-12-19 2020-07-13 Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas.

Country Status (15)

Country Link
EP (2) EP4272833A3 (es)
JP (1) JP7317017B2 (es)
KR (1) KR20200101416A (es)
CN (1) CN111836641A (es)
AU (1) AU2018389787A1 (es)
BR (1) BR112020011976A2 (es)
CA (1) CA3086327A1 (es)
ES (1) ES2963179T3 (es)
IL (1) IL275427B2 (es)
JO (1) JOP20200153A1 (es)
MA (1) MA51311A (es)
MX (3) MX2020006480A (es)
PH (1) PH12020550924A1 (es)
SG (1) SG11202005895QA (es)
WO (1) WO2019123252A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018075235A1 (en) 2016-10-17 2018-04-26 Synthetic Genomics, Inc. Recombinant virus replicon systems and uses thereof
US11845939B2 (en) 2016-12-05 2023-12-19 Janssen Pharmaceuticals, Inc. Compositions and methods for enhancing gene expression
EA202091513A1 (ru) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани Вакцины против вируса гепатита b (hbv) и их применение
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
US11083786B2 (en) 2018-01-19 2021-08-10 Janssen Pharmaceuticals, Inc. Induce and enhance immune responses using recombinant replicon systems
US20220324916A1 (en) * 2019-06-18 2022-10-13 Janssen Sciences Ireland Unlimited Company Hepatitis B Virus (HBV) Vaccines and Uses Thereof
EP3986458A1 (en) * 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Company Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof
WO2022133230A1 (en) * 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
CA3225113A1 (en) * 2021-07-16 2023-01-19 Brian Lichty Viral vaccine

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
DE69431665T2 (de) * 1993-08-02 2003-08-21 Scripps Research Inst Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US6110161A (en) 1997-04-03 2000-08-29 Electrofect As Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US5873849A (en) 1997-04-24 1999-02-23 Ichor Medical Systems, Inc. Electrodes and electrode arrays for generating electroporation inducing electrical fields
US6117660A (en) 1997-06-10 2000-09-12 Cytopulse Sciences, Inc. Method and apparatus for treating materials with electrical fields having varying orientations
BR9810369A (pt) 1997-06-30 2000-09-05 Rhone Poulenc Rorer Sa Processo de transferência de ácido nucleico para o interior de um ou mais músculos estriados, in vivo, composição, ácido mucleico e campo elétrico, e, produto de combinação
EP1100579B1 (en) 1998-07-13 2015-09-02 Inovio Pharmaceuticals, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6319901B1 (en) 1998-10-15 2001-11-20 Ichor Medical Systems, Inc. Methods for prolonging cell membrane permeability
BR0206995A (pt) 2001-02-05 2005-08-16 Stressgen Biotechnologies Corp Tratamento do vìrus da hepatite b
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US6912417B1 (en) 2002-04-05 2005-06-28 Ichor Medical Systmes, Inc. Method and apparatus for delivery of therapeutic agents
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
PT1729848E (pt) 2004-03-08 2015-08-28 Ichor Medical Systems Inc Dispositivo melhorado para uma administração electricamente mediada de agentes terapêuticos
PT2066399T (pt) 2006-10-17 2019-01-11 Inovio Pharmaceuticals Inc Dispositivos de eletroporação e métodos de usar os mesmos para eletroporação de células em mamíferos
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
AP2013007110A0 (en) * 2011-02-12 2013-09-30 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis B infection
TWI575070B (zh) * 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
AU2017241925B2 (en) 2016-03-28 2022-01-13 Ichor Medical Systems, Inc. Method and apparatus for delivery of therapeutic agents
EP3439696A4 (en) * 2016-04-06 2019-12-25 University of Washington THERAPEUTIC VACCINE AGAINST THE HEPATITIS B VIRUS (HBV) USING THE HBV CORE ANTIGEN

Also Published As

Publication number Publication date
EP4272833A3 (en) 2024-01-10
ES2963179T3 (es) 2024-03-25
CA3086327A1 (en) 2019-06-27
JP2021509107A (ja) 2021-03-18
IL275427A (en) 2020-08-31
WO2019123252A1 (en) 2019-06-27
MA51311A (fr) 2020-10-28
KR20200101416A (ko) 2020-08-27
JP7317017B2 (ja) 2023-07-28
AU2018389787A1 (en) 2020-06-25
EP3727445B1 (en) 2023-08-16
MX2020011802A (es) 2020-12-07
SG11202005895QA (en) 2020-07-29
IL275427B1 (en) 2023-12-01
IL275427B2 (en) 2024-04-01
PH12020550924A1 (en) 2021-05-31
EP3727445C0 (en) 2023-08-16
BR112020011976A2 (pt) 2020-11-24
EP4272833A2 (en) 2023-11-08
JOP20200153A1 (ar) 2022-10-30
MX2020006480A (es) 2020-09-22
EP3727445A1 (en) 2020-10-28
CN111836641A (zh) 2020-10-27

Similar Documents

Publication Publication Date Title
MX2020011804A (es) Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas.
EA202091513A1 (ru) Вакцины против вируса гепатита b (hbv) и их применение
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
PH12019550220A1 (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
PH12018500199A1 (en) Antibodies that potently neutralize hepatitis b virus and uses thereof
CY1124254T1 (el) Μεθοδοι και συνθεσεις για την προκληση προστατευτικης ανοσιας εναντι λοιμωξης ιου της ανθρωπινης ανοσοανεπαρκειας
WO2016109792A8 (en) Novel multivalent nanoparticle-based vaccines
EP4043031A3 (en) Zika viral antigen constructs
EP3439696A4 (en) THERAPEUTIC VACCINE AGAINST THE HEPATITIS B VIRUS (HBV) USING THE HBV CORE ANTIGEN
EA202090759A2 (ru) Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина
EP4234691A3 (en) Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
MX2023007395A (es) Vacunas del virus de la peste porcina africana (ppa).
ZA201707985B (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
BR112022027038A2 (pt) Vacinas de replicon de rna contra hbv
WO2016191641A3 (en) Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens
AU2017261706A1 (en) Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
PH12018502436A1 (en) Multivalent vaccines major swine viral diseases
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
PH12017500419A1 (en) Recoded arbovirus and vaccines
WO2016149643A3 (en) Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof
WO2021019235A3 (en) Hantavirus antigenic composition
WO2016169467A8 (zh) 使用仙台病毒作为载体的抗结核杆菌疫苗
AR113961A1 (es) Vacunas contra el virus de la hepatitis b (hbv) y usos de las mismas
WO2020255009A3 (en) Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
MX2017015705A (es) Modulador de celulas t potencializado capaz de modular la respuesta inmune, especificamente diseñado para su uso terapeutico como adyuvante potencializador de vacunas virales.